BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial
Am J Respir Crit Care Med
.
2022 Jun 1;205(11):1357-1360.
doi: 10.1164/rccm.202109-2182LE.
Authors
Steeve Provencher
1
,
François Potus
1
,
Pascale Blais-Lecours
1
,
Sarah Bernard
1
,
Sandra Martineau
1
,
Sandra Breuils-Bonnet
1
,
Jason Weatherald
2
,
Mike Sweeney
3
,
Ewelina Kulikowski
3
,
Olivier Boucherat
1
,
Sebastien Bonnet
1
Affiliations
1
Université Laval Québec City, Québec, Canada.
2
University of Calgary Calgary, Alberta, Canada.
3
Resverlogix Corporation Calgary, Alberta, Canada.
PMID:
35289736
DOI:
10.1164/rccm.202109-2182LE
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Humans
Nuclear Proteins
Pulmonary Arterial Hypertension*
Substances
Nuclear Proteins
Associated data
ClinicalTrials.gov/NCT03655704